-
1 Comment
Cotinga Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 11.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Cotinga Pharmaceuticals Inc gets an overall score of 1/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | CA22164W1059 |
| CurrencyCode | CAD |
| Exchange | V |
| Market Cap | 770K |
|---|---|
| Beta | 1.62 |
| Dividend Yield | 0.0% |
| Target Price | 20 |
| PE Ratio | None |
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for COT.V using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
